<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Numerous studies have identified an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the association between <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> therapies and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, postulating that agents that increase insulin levels might promote <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: This was a population-based cohort study using administrative databases from Saskatchewan Health </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-related mortality was compared among inception cohorts of <z:chebi fb="0" ids="6801">metformin</z:chebi> users and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy users </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate Cox regression was used to estimate the hazard ratio (HR) of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality, after adjusting for age, sex, insulin use, and <z:hpo ids='HP_0011010'>chronic</z:hpo> disease score </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> statistical tests were two-sided </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: We identified 10,309 new users of <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> with an average follow-up of 5.4 +/- 1.9 years (means +/- SD) </plain></SENT>
<SENT sid="7" pm="."><plain>The mean age for the cohort was 63.4 +/- 13.3 years, and 55% were men </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> mortality over follow-up was 4.9% (162 of 3,340) for <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy users, 3.5% (245 of 6,969) for <z:chebi fb="0" ids="6801">metformin</z:chebi> users, and 5.8% (84 of 1,443) for subjects who used insulin </plain></SENT>
<SENT sid="9" pm="."><plain>After multivariate adjustment, the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> cohort had greater <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality compared with the <z:chebi fb="0" ids="6801">metformin</z:chebi> cohort (adjusted HR 1.3 [95% CI 1.1-1.6]; P = 0.012) </plain></SENT>
<SENT sid="10" pm="."><plain>Insulin use was associated with an adjusted HR of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality of 1.9 (95% CI 1.5-2.4; P &lt; 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> exposed to <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and exogenous insulin had a significantly increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality compared with patients exposed to <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>It is uncertain whether this increased risk is related to a deleterious effect of <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> and insulin or a protective effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> or due to some unmeasured effect related to both choice of therapy and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
</text></document>